Pharmacopsychiatry 2003; 36 - 249
DOI: 10.1055/s-2003-825492

Dose related frequency of EPMS in patients treated with flupentixol decanoate versus risperidone

J Scherer 1, P Dobmeier 1, K Kuhn 1, W Schmaus 1
  • 1Klinik des Bezirks Oberbayern am Klinikum Garmisch-Partenkirchen, Garmisch-Partenkirchen

Study objective:We investigated in psychiatric patients as to whether extrapyramidal tolerance of the „partially atypical neurolepticum“ Flupentixol decanoate is inferior to that of the „atypical neurolepticum“ Risperidone.

Methods: 143 Risperidone and 177 Flupentixol decanoate treated patients were consecutively entered into this non-randomized open study and assessed by the Simpson-Angus-Scale regarding presence of extrapyramidal side effects (EPMS). Treatment comparisons of EPMS frequency was done by Kaplan-Meier survivorship analysis.

Results: The risk of EPMS increased with dose on both treatments. As expected, the dose-response curve was sigmoid. No more EPMS were observed on Flupentixol decanoate (mean dose 35.06±19.7mg/2 weeks) than on Risperidone (mean daily dose: 5.2±2.5mg/kg) when comparable weight standardized Haloperidol equivalence doses were used.

Conclusion: This study offers limited evidence for methodological reasons. Yet, results do not support the view that EPMS are more frequent on Flupentixol decanoate than on Risperidone when doses are comparable.